Kinases of the JNK signaling pathway may be used as therapeutic targets in stroke [24], and non-peptide synthetic JNK inhibitors have been reported (e.g., AS601245, IQ-1S, SP600125, SR-3306, and SU3327) [28]. This evidence concerns the gene MAPK8 and stroke disorder.